Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Innovation Council · Running

NEOMAG Unlocking Innovation Opportunities in Mechanobiology and Mechanomedicine

Coordinator
60nd SL, Spain
Runs
1 March 2026 to 28 February 2029
Status
Running
EU funding
€2.4m
Total cost
—
Partners
2 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101284471

What the project is doing

In the project's own words, from its summary on CORDIS.

Mechanical forces critically shape processes such as stem cell differentiation, cancer invasion, and tissue repair, yet most experimental and drug development platforms fail to capture this dimension. The lack of technologies that reproduce physiologically relevant mechanics hinders both fundamental discovery and the design of effective therapies. NeoMag EIC Transition focuses on validating the first AI-guided magneto-mechanical platform that can precisely program, sense, and control the mechanical microenvironment of living tissues under high-resolution microscopy.

Our mission: Revolutionize biomedical research to spark new scientific and therapeutic possibilities. Our integrated hardware will produce stable, high-frequency, spatially resolved deformation fields; calibrated mechanical consumables that translate actuation into reproducible tissue-level cues; and a hybrid physics+AI control stack that learns inverse mappings from desired cellular responses to actuation patterns.60ND is the lead and UC3M participates as affiliate entity.

As a UC3M spin-off, 60ND holds an exclusive license to the UC3M patent, including rights to further develop the technology andits commercialization. The team blends mechanobiology, smart materials, and data/AI with venture and startup experience, ensuring rigorous validation, stakeholder engagement with reference laboratories, and credible post-project pathways. Initial early adopters that will be pursued during this project are research labs, biotech/pharma, and CROs in organs-on-chip, regenerative medicine, and oncology, segments with clear pain points and strong purchasing power.

A RUO-first pathway, an ISO-aligned QMS foundation, and an IP/FTO strategy anchored in our exclusive UC3M license de-risk market entry and scale-up. The result is to validate a compelling venture case: a defensible technology platform, clear unit economics via recurring consumables/software, and a credible path to partnerships and distribution.

Topics

Who is involved

OrganisationCityCountryRole
60nd SLLeganesSpainCoordinator
Universidad Carlos Iii De MadridGetafe (Madrid)SpainThird party

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI